{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:04:38Z","timestamp":1787313878692,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T00:00:00Z","timestamp":1526947200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["#04R\/2016"],"award-info":[{"award-number":["#04R\/2016"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["#PS15\/05 J.G."],"award-info":[{"award-number":["#PS15\/05 J.G."]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Faculty, University of Leipzig","award":["#990101-089"],"award-info":[{"award-number":["#990101-089"]}]},{"name":"Verein zusammen gegen den Krebs e.V."},{"name":"Ein Herz f\u00fcr Kinder e.V."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00277-018-3373-y","type":"journal-article","created":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T18:58:53Z","timestamp":1526929133000},"page":"1757-1765","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients"],"prefix":"10.1007","volume":"97","author":[{"given":"Marius","family":"Bill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madlen","family":"Jentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kloss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Goldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Beinicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"H\u00e4ntschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"P\u00f6nisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Behre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg-Nikolaus","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thoralf","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schwind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,22]]},"reference":[{"issue":"10","key":"3373_CR1","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrclinonc.2012.150","volume":"9","author":"JJ Cornelissen","year":"2012","unstructured":"Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornh\u00e4user M, Juliusson G, R\u00e5cil Z, Rowe JM, Russell N, Mohty M, L\u00f6wenberg B, Soci\u00e9 G, Niederwieser D, Ossenkoppele GJ (2012) The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission. An integrated-risk adapted approach. Nat Rev Clin Oncol 9(10):579\u2013590. \n                    https:\/\/doi.org\/10.1038\/nrclinonc.2012.150","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"3373_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H D\u00f6hner","year":"2010","unstructured":"D\u00f6hner H, Estey EH, Amadori S, Appelbaum FR, B\u00fcchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, L\u00f6wenberg B, Bloomfield CD, European LeukemiaNet (2010) Diagnosis and management of acute myeloid leukemia in adults. Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453\u2013474. \n                    https:\/\/doi.org\/10.1182\/blood-2009-07-235358","journal-title":"Blood"},{"issue":"12","key":"3373_CR3","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373(12):1136\u20131152. \n                    https:\/\/doi.org\/10.1056\/NEJMra1406184","journal-title":"N Engl J Med"},{"issue":"1","key":"3373_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ajh.22246","volume":"87","author":"EH Estey","year":"2012","unstructured":"Estey EH (2012) Acute myeloid leukemia. 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87(1):89\u201399. \n                    https:\/\/doi.org\/10.1002\/ajh.22246","journal-title":"Am J Hematol"},{"issue":"5","key":"3373_CR5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1507471","volume":"374","author":"A Ivey","year":"2016","unstructured":"Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths M, Solomon E, McCaughan F, Linch DC, Gale RE, Vyas P, Freeman SD, Russell N, Burnett AK, Grimwade D, UK National Cancer Research Institute AML Working Group (2016) Assessment of minimal residual disease in standard-risk AML. N Engl J Med 374(5):422\u2013433. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1507471","journal-title":"N Engl J Med"},{"issue":"15","key":"3373_CR6","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","volume":"36","author":"Sylvie D. Freeman","year":"2018","unstructured":"Freeman SD, Hills RK, Virgo P et al (2018) Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. J Clin Oncol: JCO.2017.76.3425. \n                    https:\/\/doi.org\/10.1200\/JCO.2017.76.3425","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"3373_CR7","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ, Gradowska PL, Meijer R, Cloos J, Biemond BJ, Graux C, van Marwijk Kooy M, Manz MG, Pabst T, Passweg JR, Havelange V, Ossenkoppele GJ, Sanders MA, Schuurhuis GJ, L\u00f6wenberg B, Valk PJM (2018) Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med 378(13):1189\u20131199. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1716863","journal-title":"N Engl J Med"},{"issue":"4","key":"3373_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, L\u00f6wenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447. \n                    https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"issue":"5","key":"3373_CR9","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/sj.leu.2404637","volume":"21","author":"W-C Chou","year":"2007","unstructured":"Chou W-C, Tang J-L, Wu S-J, Tsay W, Yao M, Huang SY, Huang KC, Chen CY, Huang CF, Tien HF (2007) Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 21(5):998\u20131004. \n                    https:\/\/doi.org\/10.1038\/sj.leu.2404637","journal-title":"Leukemia"},{"issue":"6","key":"3373_CR10","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/sj.leu.2404149","volume":"20","author":"P Gorello","year":"2006","unstructured":"Gorello P, Cazzaniga G, Alberti F, Dell'Oro MG, Gottardi E, Specchia G, Roti G, Rosati R, Martelli MF, Diverio D, Coco FL, Biondi A, Saglio G, Mecucci C, Falini B (2006) Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 20(6):1103\u20131108. \n                    https:\/\/doi.org\/10.1038\/sj.leu.2404149","journal-title":"Leukemia"},{"issue":"8","key":"3373_CR11","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3324\/haematol.2014.104133","volume":"99","author":"M Hubmann","year":"2014","unstructured":"Hubmann M, Kohnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander SK, Subklewe M, Sauerland MC, Berdel WE, Buchner T, Wormann B, Hiddemann W, Spiekermann K (2014) Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse. Haematologica 99(8):1317\u20131325. \n                    https:\/\/doi.org\/10.3324\/haematol.2014.104133","journal-title":"Haematologica"},{"issue":"1","key":"3373_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2013-01-479188","volume":"122","author":"J Kr\u00f6nke","year":"2013","unstructured":"Kr\u00f6nke J, Bullinger L, Teleanu V et al (2013) Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood 122(1):100\u2013108. \n                    https:\/\/doi.org\/10.1182\/blood-2013-01-479188","journal-title":"Blood"},{"issue":"11","key":"3373_CR13","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2009-03-213389","volume":"114","author":"S Schnittger","year":"2009","unstructured":"Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, Haferlach C, Haferlach T (2009) Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 114(11):2220\u20132231. \n                    https:\/\/doi.org\/10.1182\/blood-2009-03-213389","journal-title":"Blood"},{"issue":"8","key":"3373_CR14","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/sj.leu.2403809","volume":"19","author":"M Weisser","year":"2005","unstructured":"Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T, Schnittger S (2005) Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 19(8):1416\u20131423. \n                    https:\/\/doi.org\/10.1038\/sj.leu.2403809","journal-title":"Leukemia"},{"issue":"23","key":"3373_CR15","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1182\/blood-2014-05-577593","volume":"124","author":"D Grimwade","year":"2014","unstructured":"Grimwade D, Freeman SD (2014) Defining minimal residual disease in acute myeloid leukemia. Which platforms are ready for \u201cprime time\u201d? Blood 124(23):3345\u20133355. \n                    https:\/\/doi.org\/10.1182\/blood-2014-05-577593","journal-title":"Blood"},{"issue":"14","key":"3373_CR16","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","volume":"120","author":"JAL Yin","year":"2012","unstructured":"Yin JAL, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK (2012) Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse. Results of the United Kingdom MRC AML-15 trial. Blood 120(14):2826\u20132835. \n                    https:\/\/doi.org\/10.1182\/blood-2012-06-435669","journal-title":"Blood"},{"issue":"19","key":"3373_CR17","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","volume":"29","author":"J Kr\u00f6nke","year":"2011","unstructured":"Kr\u00f6nke J, Schlenk RF, Jensen K-O, Tsch\u00fcrtz F, Corbacioglu A, Gaidzik VI, Paschka P, Onken S, Eiwen K, Habdank M, Sp\u00e4th D, L\u00fcbbert M, Wattad M, Kindler T, Salih HR, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler HG, Krauter J, Ganser A, G\u00f6hring G, Schlegelberger B, D\u00f6hner H, D\u00f6hner K (2011) Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia. A study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol Off J Am Soc Clin Oncol 29(19):2709\u20132716. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.35.0371","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"3373_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","volume":"34","author":"D Araki","year":"2016","unstructured":"Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, Mielcarek M, Estey EH, Appelbaum FR, Walter RB (2016) Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol Off J Am Soc Clin Oncol 34(4):329\u2013336. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.63.3826","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"3373_CR19","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/leu.2016.46","volume":"30","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB, Mielcarek M, Estey EH, Appelbaum FR, Walter RB (2016) Pre- and post-transplant quantification of measurable (\u2018minimal\u2019) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia 30(7):1456\u20131464. \n                    https:\/\/doi.org\/10.1038\/leu.2016.46","journal-title":"Leukemia"},{"issue":"9","key":"3373_CR20","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","volume":"130","author":"L Muffly","year":"2017","unstructured":"Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D\u2019Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A (2017) Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood 130(9):1156\u20131164. \n                    https:\/\/doi.org\/10.1182\/blood-2017-03-772368","journal-title":"Blood"},{"issue":"6","key":"3373_CR21","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/bmt.2017.42","volume":"52","author":"M Bill","year":"2017","unstructured":"Bill M, Jentzsch M, Grimm J, Schubert K, Lange T, Cross M, Behre G, Vucinic V, P\u00f6nisch W, Franke GN, Niederwieser D, Schwind S (2017) Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning. Bone Marrow Transplant 52(6):932\u2013935. \n                    https:\/\/doi.org\/10.1038\/bmt.2017.42","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"3373_CR22","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1200\/JCO.2009.27.1460","volume":"28","author":"B Gyurkocza","year":"2010","unstructured":"Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA, Langston AA, Pulsipher MA, Bredeson CN, Maziarz RT, Bruno B, Petersen FB, Maris MB, Agura E, Yeager A, Bethge W, Sahebi F, Appelbaum FR, Maloney DG, Sandmaier BM (2010) Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol 28(17):2859\u20132867. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.27.1460","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"3373_CR23","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1200\/JCO.2005.03.1765","volume":"24","author":"U Hegenbart","year":"2006","unstructured":"Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H, Cordonnier C, Rio B, Gratwohl A, Lange T, al-Ali H, Storer B, Maloney D, McSweeney P, Chauncey T, Agura E, Bruno B, Maziarz RT, Petersen F, Storb R (2006) Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol Off J Am Soc Clin Oncol 24(3):444\u2013453. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.03.1765","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"3373_CR24","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/0360-3016(82)90083-9","volume":"8","author":"ED Thomas","year":"1982","unstructured":"Thomas ED, Clift RA, Hersman J, Sanders JE, Stewart P, Buckner CD, Fefer A, McGuffin R, Smith JW, Storb R (1982) Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation. Int J Radiat Oncol Biol Phys 8(5):817\u2013821","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"3373_CR25","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3324\/haematol.11202","volume":"92","author":"M Palmisano","year":"2007","unstructured":"Palmisano M, Grafone T, Ottaviani E, Testoni N, Baccarani M, Martinelli G (2007) NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. Haematologica 92(9):1268\u20131269","journal-title":"Haematologica"},{"issue":"10","key":"3373_CR26","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.21873\/anticanres.11130","volume":"36","author":"M Karas","year":"2016","unstructured":"Karas M, Steinerova K, Lysak D et al (2016) Pre-transplant quantitative determination of NPM1 mutation significantly predicts outcome of ailogeneic hematopoietic stem cell transplantation in patients with normal karyotype AML in complete remission. Anticancer Res 36(10):5487\u20135498","journal-title":"Anticancer Res"},{"issue":"7","key":"3373_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.46","volume":"6","author":"S Kayser","year":"2016","unstructured":"Kayser S, Benner A, Thiede C, Martens U, Huber J, Stadtherr P, Janssen JWG, R\u00f6llig C, Uppenkamp MJ, Bochtler T, Hegenbart U, Ehninger G, Ho AD, Dreger P, Kr\u00e4mer A (2016) Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Blood Cancer J 6(7):e449. \n                    https:\/\/doi.org\/10.1038\/bcj.2016.46","journal-title":"Blood Cancer J"},{"issue":"2","key":"3373_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","volume":"35","author":"Marie Balsat","year":"2017","unstructured":"Balsat M, Renneville A, Thomas X et al (2016) Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association group. JCO: JCO.2016.67.1875. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.67.1875","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"3373_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1182\/blood-2012-10-461749","volume":"122","author":"N Shayegi","year":"2013","unstructured":"Shayegi N, Kramer M, Bornhauser M, Schaich M, Schetelig J, Platzbecker U, Rollig C, Heiderich C, Landt O, Ehninger G, Thiede C, on behalf of the Study Alliance Leukemia (SAL) (2013) The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood 122(1):83\u201392. \n                    https:\/\/doi.org\/10.1182\/blood-2012-10-461749","journal-title":"Blood"},{"issue":"10","key":"3373_CR30","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","volume":"122","author":"RB Walter","year":"2013","unstructured":"Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, Fang M, Gyurkocza B, Delaney C, Radich JP, Estey EH, Appelbaum FR (2013) Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 122(10):1813\u20131821. \n                    https:\/\/doi.org\/10.1182\/blood-2013-06-506725","journal-title":"Blood"},{"issue":"4","key":"3373_CR31","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jmoldx.2017.03.005","volume":"19","author":"N Mencia-Trinchant","year":"2017","unstructured":"Mencia-Trinchant N, Hu Y, Alas MA, Ali F, Wouters BJ, Lee S, Ritchie EK, Desai P, Guzman ML, Roboz GJ, Hassane DC (2017) Minimal residual disease monitoring of acute myeloid leukemia by massively multiplex digital PCR in patients with NPM1 mutations. J Mol Diagn: JMD 19(4):537\u2013548. \n                    https:\/\/doi.org\/10.1016\/j.jmoldx.2017.03.005","journal-title":"J Mol Diagn: JMD"},{"issue":"2","key":"3373_CR32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1046\/j.1365-2141.2000.02178.x","volume":"110","author":"JY Cahn","year":"2000","unstructured":"Cahn JY, Labopin M, Sierra J, Blaise D, Reiffers J, Ferrant A, Bergmann L, Visani G, Cornelissen J, de Witte T, Bosi A, Frassoni F, Gorin NC, for the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2000) No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110(2):308\u2013314","journal-title":"Br J Haematol"},{"issue":"6","key":"3373_CR33","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/bmt.2012.236","volume":"48","author":"R Martino","year":"2013","unstructured":"Martino R, de Wreede L, Fiocco M et al (2013) Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts. A report from EBMT. Bone Marrow Transplant 48(6):761\u2013770. \n                    https:\/\/doi.org\/10.1038\/bmt.2012.236","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"3373_CR34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/leu.2014.173","volume":"29","author":"RB Walter","year":"2015","unstructured":"Walter RB, Gyurkocza B, Storer BE, Godwin CD, Pagel JM, Buckley SA, Sorror ML, Wood BL, Storb R, Appelbaum FR, Sandmaier BM (2015) Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia 29(1):137\u2013144. \n                    https:\/\/doi.org\/10.1038\/leu.2014.173","journal-title":"Leukemia"},{"issue":"3","key":"3373_CR35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/leu.2011.234","volume":"26","author":"U Platzbecker","year":"2012","unstructured":"Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, Klut IM, Knoth H, R\u00f6llig C, Schetelig J, Mohr B, Graehlert X, Ehninger G, Bornh\u00e4user M, Thiede C (2012) Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT. Results of the RELAZA trial. Leukemia 26(3):381\u2013389. \n                    https:\/\/doi.org\/10.1038\/leu.2011.234","journal-title":"Leukemia"},{"issue":"10","key":"3373_CR36","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.bbmt.2015.05.026","volume":"21","author":"I Pusic","year":"2015","unstructured":"Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, Vij R, Abboud CN, Stockerl-Goldstein KE, Jacoby MA, Uy GL, Westervelt P, DiPersio JF (2015) Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant 21(10):1761\u20131769. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2015.05.026","journal-title":"Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant"},{"issue":"14","key":"3373_CR37","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1182\/blood-2011-09-380386","volume":"119","author":"C-H Yan","year":"2012","unstructured":"Yan C-H, Liu D-H, Liu K-Y, Xu LP, Liu YR, Chen H, Han W, Wang Y, Qin YZ, Huang XJ (2012) Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 119(14):3256\u20133262. \n                    https:\/\/doi.org\/10.1182\/blood-2011-09-380386","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3373-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3373-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3373-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T12:17:33Z","timestamp":1558527453000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3373-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,22]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["3373"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3373-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,22]]},"assertion":[{"value":"22 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent for participation in studies was obtained in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}